𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Inhibitory effect on expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma

✍ Scribed by Sasamura, H; Takahashi, A; Miyao, N; Yanase, M; Masumori, N; Kitamura, H; Itoh, N; Tsukamoto, T

Book ID
109997163
Publisher
Nature Publishing Group
Year
2002
Tongue
English
Weight
148 KB
Volume
86
Category
Article
ISSN
0007-0920

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Macrophage migration inhibitory factor:
Macrophage migration inhibitory factor: Roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma
✍ Yi Ren; Hong-Teng Tsui; Ronnie Tung-Ping Poon; Irene Oi-Lin Ng; Zhi Li; Yongxion πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 French βš– 518 KB

## Abstract Macrophage migration inhibitory factor (MIF) may contribute to multiple aspects of tumor progression, including control of cell proliferation, differentiation, cell survival and angiogenesis. However, the potential roles of MIF in regulating hepatocellular carcinoma (HCC) tumor cell mig

Angiogenic factors expressed by human pr
Angiogenic factors expressed by human prostatic cell lines: Effect on endothelial cell growth in vitro
✍ Hepburn, Peter J.; Griffiths, Keith; Harper, Maureen E. πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 213 KB πŸ‘ 2 views

## Background: Antiangiogenic therapy for prostatic cancer should offer additional ways of combating tumor progression. knowledge of the possible angiogenic factors expressed by prostate cancer cell lines would therefore assist in the design and testing of such potential treatments. ## Methods: C

The inhibitory effect of connexin 32 gen
The inhibitory effect of connexin 32 gene on metastasis in renal cell carcinoma
✍ Hiromi Sato; Hiromi Hagiwara; Hironobu Senba; Keiko Fukumoto; Yoji Nagashima; Hi πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 267 KB

## Abstract We have previously reported that connexin (Cx) 32 gene, a member of gap junctions, was specifically downregulated in human renal cell carcinoma (RCC) and it acts as a tumor suppressor against RCC. Because there is no standard therapy for advanced RCC, we investigated the anti‐metastatic